AKRO Akero Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AKRO

Price (delayed)

$20.7

Market cap

$1.17B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.89

Enterprise value

$956.93M

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, ...

Highlights
Akero Therapeutics's quick ratio has surged by 56% YoY and by 47% QoQ
AKRO's equity has surged by 64% year-on-year but it is down by 8% since the previous quarter
AKRO's debt has surged by 143% year-on-year
AKRO's net income is down by 35% YoY and by 27% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.akerotx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of AKRO
Market
Shares outstanding
56.3M
Market cap
$1.17B
Enterprise value
$956.93M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$148.66M
EBITDA
-$148.4M
Free cash flow
-$145.37M
Per share
EPS
-$2.89
Free cash flow per share
-$2.77
Book value per share
$9.61
Revenue per share
$0
TBVPS
$11.04
Balance sheet
Total assets
$580.27M
Total liabilities
$44.97M
Debt
$25.78M
Equity
$535.31M
Working capital
$540.83M
Liquidity
Debt to equity
0.05
Current ratio
29.27
Quick ratio
28.75
Net debt/EBITDA
1.4
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-27.2%
Return on equity
-29.7%
Return on invested capital
-57.2%
Return on capital employed
-26.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKRO stock price

How has the Akero Therapeutics stock price performed over time
Intraday
-1.43%
1 week
-4.17%
1 month
-17.63%
1 year
-53.96%
YTD
-11.35%
QTD
-18.05%

Financial performance

How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$172.87M
Net income
-$151.76M
Gross margin
N/A
Net margin
N/A
Akero Therapeutics's operating income has plunged by 50% YoY and by 27% from the previous quarter
AKRO's net income is down by 35% YoY and by 27% QoQ

Growth

What is Akero Therapeutics's growth rate over time

Valuation

What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
2.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has decreased by 27% QoQ
AKRO's equity has surged by 64% year-on-year but it is down by 8% since the previous quarter
The stock's P/B is 49% below its 5-year quarterly average of 4.3 and 48% below its last 4 quarters average of 4.2

Efficiency

How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on invested capital has surged by 90% YoY and by 4.2% QoQ
Akero Therapeutics's return on equity has increased by 36% YoY but it has decreased by 14% QoQ
The ROA has grown by 34% YoY but it has contracted by 14% from the previous quarter

Dividends

What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKRO.

Financial health

How did Akero Therapeutics financials performed over time
The company's total assets has surged by 63% YoY but it fell by 9% QoQ
The current ratio has soared by 57% year-on-year and by 45% since the previous quarter
AKRO's debt is 95% smaller than its equity
AKRO's debt has surged by 143% year-on-year
The debt to equity has soared by 67% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.